Corticosteroid minimization in renal transplantation: Careful patient selection enables feasibility

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 4

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Evidence-Based Medicine

World J Transplant. Dec 24, 2016; 6(4): 759-766
Published online Dec 24, 2016. doi: 10.5500/wjt.v6.i4.759

Table 4 Characteristics of corticosteroid avoidance/withdrawal trials in immunologically high-risk and in pediatric patients

Ref.	Patient number	Immunological risk	Timing of CS withdrawal	Induction immunosuppression	Maintenance immunosuppression	Acute rejection (%)	Allograft/patient survival (%)	Follow-up (mo)
Immunologically high-risk patients
Thomas et al[26]	11	PRA > 20%, or	No CS	Alemtuzumab	TAC	18.2	86/100	12
Thomas et al[26]	10	repeat transplant	Day 5	ATG	TAC, MMF	37.5	88/88	12
Hanaway et al[17]	164	PRA > 20%, or	Day 5	Alemtuzumab	TAC, MMF	18	91/99	36
	171	black race, or repeat transplant	Day 5	ATG		15	84/91

Pediatric patients
Grenda et al[28]	98	Low/moderate	Day 4	Daclizumab	TAC, MMF	10.2	97/99	6
Grenda et al[28]	98	(PRA < 50%)	Standard CS	No induction	TAC, MMF	7.1	97/100	6
Höcker et al[29]	23	Moderate/high (PRA < 80%)	After year 1	No	CsA, MMF	4	100/100	24
Höcker et al[29]	19	Moderate/high (PRA < 80%)	Standard CS	No	CsA, MMF	10	100/100	24

ATG: Antithymocyte globulin; CS: Corticosteroids; CsA: Cyclosporine; MMF: Mycophenolate mofetil; PRA: Panel-reactive antibodies; TAC: Tacrolimus.

Citation: Vlachopanos G, Bridson JM, Sharma A, Halawa A. Corticosteroid minimization in renal transplantation: Careful patient selection enables feasibility. World J Transplant 2016; 6(4): 759-766
URL: https://www.wjgnet.com/2220-3230/full/v6/i4/759.htm
DOI: https://dx.doi.org/10.5500/wjt.v6.i4.759

Vlachopanos G, Bridson JM, Sharma A, Halawa A. Corticosteroid minimization in renal transplantation: Careful patient selection enables feasibility. World J Transplant 2016; 6(4): 759-766 [PMID: 28058228 DOI: 10.5500/wjt.v6.i4.759]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.